Anti-CGRP mAbs, marketed since the end of 2019 in Spain, were used by 1.7% of migraine patients treated between May 2020 and April 2022, and by 5.7% of those treated with a preventive medication during that period. This evidence concerns the gene CALCA and migraine disorder.